Clinical efficacy and mechanism of mesenchymal stromal cells in treatment of COVID-19

Lu, Kun Ping; Geng, Shi-Tao; Tang, Shi-Kai; Yang, Hua; Xiong, Wei; Xu, Feifei; Yuan, Qijun; Xiao, Xian; Huang, Ren‐qiang; Liang, Haihui; Chen, Zhipeng; Qian, Chuanyun; Li, Yang; Wang, Songqing

doi:10.1186/s13287-022-02743-0

Cited by 10 publications

(6 citation statements)

References 61 publications

(89 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A smaller but growing number of phase 2 efficacy trials have demonstrated efficacy in some cases but not in others. The most extensive experience to date is in investigations of systemic MSC administration in patients with either non-COVID or COVID19-related ARDS with recent meta-analyses of COVID-19 related-ARDS demonstrating significant benefits of MSC administration ( Khoury et al, 2020 ; Qu et al, 2020 ; Zhu et al, 2021 ; Kirkham et al, 2022 ; Lu et al, 2022 ). Intensive deliberation about the varying outcomes in these trials has highlighted ongoing issues with investigations of MSC administration not just in patients with respiratory diseases or critical illnesses but in a wider range of conditions.…”

Section: Overview Of Lung Regenerative Medicinementioning

confidence: 99%

What is the need and why is it time for innovative models for understanding lung repair and regeneration?

Weiss

2023

Front. Pharmacol.

View full text Add to dashboard Cite

Advances in tissue engineering continue at a rapid pace and have provided novel methodologies and insights into normal cell and tissue homeostasis, disease pathogenesis, and new potential therapeutic strategies. The evolution of new techniques has particularly invigorated the field and span a range from novel organ and organoid technologies to increasingly sophisticated imaging modalities. This is particularly relevant for the field of lung biology and diseases as many lung diseases, including chronic obstructive pulmonary disease (COPD) and idiopathic fibrosis (IPF), among others, remain incurable with significant morbidity and mortality. Advances in lung regenerative medicine and engineering also offer new potential avenues for critical illnesses such as the acute respiratory distress syndrome (ARDS) which also continue to have significant morbidity and mortality. In this review, an overview of lung regenerative medicine with focus on current status of both structural and functional repair will be presented. This will serve as a platform for surveying innovative models and techniques for study, highlighting the need and timeliness for these approaches.

show abstract

Section: Overview Of Lung Regenerative Medicinementioning

confidence: 99%

What is the need and why is it time for innovative models for understanding lung repair and regeneration?

Weiss

2023

Front. Pharmacol.

View full text Add to dashboard Cite

show abstract

“…For instance, they can inhibit the abnormal activation and overproliferation of T-helper 1 (Th1) cells by regulating the NKG2D signaling pathways to modulate the Th1/Th2 balance. [165,166] Moreover, miRNAs in MSC-EVs, such as miR-27a-3p, miRNA Let-7, and miR-100, are able to promote macrophage polarization from the proinflammatory M1 type to the anti-inflammatory M2 type. [153,167,168] In addition to mammalian cells and their EVs, some edible plant-derived biomaterials also contain exosome-like nanoparticles (ELNs) with anti-inflammatory and drug-delivery functions.…”

Section: Anti-inflammationmentioning

confidence: 99%

“…For instance, they can inhibit the abnormal activation and overproliferation of T‐helper 1 (Th1) cells by regulating the NKG2D signaling pathways to modulate the Th1/Th2 balance. [ 165,166 ] Moreover, miRNAs in MSC‐EVs, such as miR‐27a‐3p, miRNA Let‐7, and miR‐100, are able to promote macrophage polarization from the proinflammatory M1 type to the anti‐inflammatory M2 type. [ 153,167,168 ]…”

Section: Applications Of Cell‐based Biomaterials In Coronavirus Disea...mentioning

confidence: 99%

Cell‐Based Biomaterials for Coronavirus Disease 2019 Prevention and Therapy

Wang

Xie

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

Coronavirus disease 2019 (COVID-19) continues to threaten human health, economic development, and national security. Although many vaccines and drugs have been explored to fight against the major pandemic, their efficacy and safety still need to be improved. Cell-based biomaterials, especially living cells, extracellular vesicles, and cell membranes, offer great potential in preventing and treating COVID-19 owing to their versatility and unique biological functions. In this review, the characteristics and functions of cell-based biomaterials and their biological applications in COVID-19 prevention and therapy are described. First the pathological features of COVID-19 are summarized, providing enlightenment on how to fight against COVID-19. Next, the classification, organization structure, characteristics, and functions of cell-based biomaterials are focused on. Finally, the progress of cell-based biomaterials in overcoming COVID-19 in different aspects, including the prevention of viral infection, inhibition of viral proliferation, anti-inflammation, tissue repair, and alleviation of lymphopenia are comprehensively described. At the end of this review, a look forward to the challenges of this aspect is presented.

show abstract

“…A report of the first compassionate use of MSCs in a Chinese patient with severe SARS-CoV-2 infection was published in January 2019 [ 13 , 14 ]. The promising results of this study have led to many clinical trials evaluating one or repeated infusions of MSCs themselves under the status of advanced therapy drugs [ 14 , 15 , 16 ] or using MSCs as raw material for extracellular vesicle (EV) production [ 17 , 18 ].…”

Section: Introductionmentioning

confidence: 99%

Scale-Up of Academic Mesenchymal Stromal Cell Production

Laroye

Gauthier

Morello³

et al. 2023

JCM

View full text Add to dashboard Cite

Background: Many clinical trials have reported the use of mesenchymal stromal cells (MSCs) following the indication of severe SARS-CoV-2 infection. However, in the COVID19 pandemic context, academic laboratories had to adapt a production process to obtain MSCs in a very short time. Production processes, especially freezing/thawing cycles, or culture medium have impacts on MSC properties. We evaluated the impact of an intermediate cryopreservation state during MSC culture to increase production yields. Methods: Seven Wharton’s jelly (WJ)-MSC batches generated from seven different umbilical cords with only one cryopreservation step and 13 WJ-MSC batches produced with intermediate freezing were formed according to good manufacturing practices. The identity (phenotype and clonogenic capacities), safety (karyotype, telomerase activity, sterility, and donor qualification), and functionality (viability, mixed lymphocyte reaction) were analyzed. Results: No significant differences between MSC production processes were observed, except for the clonogenic capacity, which was decreased, although it always remained above our specifications. Conclusions: Intermediate cryopreservation allows an increase in the production yield and has little impact on the basic characteristics of MSCs.

show abstract

Clinical efficacy and mechanism of mesenchymal stromal cells in treatment of COVID-19

Cited by 10 publications

References 61 publications

What is the need and why is it time for innovative models for understanding lung repair and regeneration?

What is the need and why is it time for innovative models for understanding lung repair and regeneration?

Cell‐Based Biomaterials for Coronavirus Disease 2019 Prevention and Therapy

Scale-Up of Academic Mesenchymal Stromal Cell Production

Contact Info

Product

Resources

About